文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

脑啡肽原作为生物标志物与急性肾损伤相关:一项系统评价、荟萃分析与试验序贯分析

Proenkephalin as a biomarker correlates with acute kidney injury: a systematic review with meta-analysis and trial sequential analysis.
PubMed 文献 · Crit Care · 2023-12-07
一句话结论在11项观察性研究、3969例患者中,脑啡肽原(PENK)以57.3 pmol/L为界值早期识别急性肾损伤的汇总敏感度0.69、特异度0.76、诊断准确度0.77。

本文为系统评价与荟萃分析,检索PubMed、Embase、Cochrane、ClinicalTrials.gov及Cnki.net至2023年6月26日,纳入11项观察性研究共3969例患者,急性肾损伤(AKI)发生率为23.4%(929/3969)。PENK早期检测AKI的最佳界值为57.3 pmol/L,汇总敏感度0.69(95%CI 0.62-0.75)、特异度0.76(95%CI 0.68-0.82)、诊断准确度0.77(95%CI 0.73-0.81)。作者认为PENK作为早期检测AKI的生物标志物具有显著潜力。

要点

  • PENK早期检测AKI的汇总敏感度0.69(95%CI 0.62-0.75)、特异度0.76(95%CI 0.68-0.82),最佳界值57.3 pmol/L。
  • 汇总诊断准确度(SROC曲线下面积)为0.77(95%CI 0.73-0.81),合并阳性似然比2.83(95%CI 2.06-3.88)、阴性似然比0.41(95%CI 0.33-0.52)。
  • 有高血压或心力衰竭病史的患者,PENK与AKI相关的特异度更低。
  • 本分析纳入11项观察性研究、3969例患者,AKI发生率为23.4%(929/3969)。

适用人群与场景

  • 纳入11项观察性研究、共3969例患者,急性肾损伤发生率为23.4%(929/3969)。

诊断标准与关键阈值

  • PENK早期检测AKI的最佳界值为57.3 pmol/L。

研究设计与关键结果

  • 系统评价与荟萃分析,纳入11项观察性研究共3969例患者,AKI发生率23.4%(929/3969)。
  • PENK早期检测AKI的最佳界值为57.3 pmol/L,汇总敏感度0.69(95%CI 0.62-0.75)、特异度0.76(95%CI 0.68-0.82)。
  • 合并阳性似然比2.83(95%CI 2.06-3.88),合并阴性似然比0.41(95%CI 0.33-0.52)。
  • SROC曲线汇总诊断准确度0.77(95%CI 0.73-0.81)。
  • 有高血压或心力衰竭病史的患者,PENK与AKI相关的特异度更低。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入11项观察性研究;采用GRADE标准评估证据质量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为PENK作为早期检测AKI的生物标志物具有显著潜力,最佳界值为57.3 pmol/L。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Proenkephalin A 119-159 (PENK) is freely filtered in the glomerulus with plasma levels correlating with glomerular filtration rate. Therefore, PENK has been proposed as an early indicator of acute kidney injury (AKI) although its performance is dependent on the clinical setting. This meta-analysis aimed to investigate the correlation between PENK levels and the development of AKI.

METHODS: We conducted a comprehensive search on the PubMed, Embase, Cochrane databases, the website ClinicalTrials.gov and Cnki.net until June 26, 2023. Summary receiver operating characteristic (SROC) curves were used to amalgamate the overall test performance. Diagnostic odds ratio (DOR) was employed to compare the diagnostic accuracy of PENK with other biomarkers. Quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria.

RESULTS: We incorporated 11 observational studies with 3969 patients with an incidence of AKI of 23.4% (929 out of 3969 patients) with the best optimal cutoff value of PENK for early detection of AKI being 57.3 pmol/L. The overall sensitivity and specificity of PENK in identifying AKI were 0.69 (95% CI 0.62-0.75) and 0.76 (95% CI 0.68-0.82), respectively. The combined positive likelihood ratio (LR) stood at 2.83 (95% CI 2.06-3.88), and the negative LR was 0.41 (95% CI 0.33-0.52). The SROC curve showcased pooled diagnostic accuracy of 0.77 (95% CI 0.73-0.81). Interestingly, patients with a history of hypertension or heart failure demonstrated a lower specificity of PENK in correlating the development of AKI.

CONCLUSION: Our results indicate that PENK possesses significant potential as a biomarker for the early detection of the development of AKI, using a cutoff point of 57.3 pmol/L for PENK.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Lin LC, Chuan MH, Liu JH, et al. Proenkephalin as a biomarker correlates with acute kidney injury: a systematic review with meta-analysis and trial sequential analysis. Crit Care. 2023. PMID: 38057904. doi:10.1186/s13054-023-04747-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。